ScripsAmerica, Inc. announced that the Company has entered into a business management agreement with a New Jersey compounding pharmacy. The agreement states that ScripsAmerica will manage all business operations of the pharmacy which specializes in compounding topical pain creams, in exchange for a percentage of its total revenue. These creams are experiencing growing demand because they provide an effective alternative to pills that can be more easily ingested in higher doses than originally prescribed.

Since February 14th ScripsAmerica's efforts have generated $57,000 in revenue. The company has previously announced plans to enter the rapidly growing compounding pharmacy market to create a new revenue stream and increase shareholder value. The compounding pharmacy industry is set to benefit from improved conditions over the next five years, according to a November 2012 IBIS research report.

A key factor contributing to the overall growth of compounding pharmacies is the introduction of regulation US Pharmacopeia (USP) chapter 797. This regulation took effect in 2004 and was developed to help improve patient safety by developing standards designed to reduce large content error and contamination errors in compounded sterile products.